By Huang Jianwen King & Wood Mallesons’Commercial & Regulatory Group
On July 25, 2016, the China Food and Drug Administration (“CFDA”) published the Administrative Provisions for Drug Registration (Revision) (the “Draft for Comment”) and submitted the Draft for Comment for public opinions. Composing of 8 chapters and 147 provisions in total, the Draft for Comment differs in length and structure from the current Administrative Provisions for Drug Registration (the “Current Provisions”) published in 2007. Highly instructive, the Draft for Comment reflects a series of fundamental reforms in medical industry since 2015.
Read full article, please click here.